Experience with Levilimab in Ambulatory Practice (in the Provision of Primary Medical and Social Care)

Purpose: The aim of the study was to confirm the effectiveness of the drug at the pre–hospital stage to prevent the development of severe forms of infection requiring hospitalization.
Materials and methods: To collect clinical and epidemiological data in the 2021-2022 season, an active prospective cohort study approach was used to assess the efficacy and safety of levilimab in patients with confirmed new coronavirus infection in outpatient settings. The comparison involved patients who received 1 or 2 doses of levilimab in combination with standard therapy (n=283) and patients who voluntarily refused to use levilimab and received only standard therapy (n=223).
Results: According to the study, patients who received levilimab (1 or 2 doses) had a lower frequency of hospitalizations compared to patients who had standard therapy taking into account the same laboratory indicators of CRP (mg/l) in the two study groups. Younger patients (under 30 years of age) had a much lower risk of hospitalization than older patients, regardless of the use of levilimab. There is also a direct correlation between the age of patients and their risk of hospitalization. It was revealed that with the refusal of the use of the Levilimab monoclonal antibody, an increase in age for every 10 years affected an increase in the risk of hospitalization by up to 10%. Patients after 50 years who refused levilimab and took standard therapy were hospitalized several times more often than patients with the same therapy who performed levilimab injection. Patients who received one dose (162 mg) or two doses (324 mg) of the drug had the best effect of the therapy – they had the lowest frequency of hospitalizations compared to patients who voluntarily refused the administration of a monoclonal antibody. When refusing to use levilimab, the probability of hospitalization increased to 60%, which was crucial for those patients who did not have a single injection.